Valeant Boosts Bid For Allergan

May 29 2014 | 12:19pm ET

Valeant Pharmaceuticals International has increased its offer for Allergan Inc. by 7%, offering more cash and additional payments in a deal backed by Pershing Square Capital Management.

Valeant increased its offer to nearly $50 billion. The Canadian company also increased the amount of cash in the deal by $10 per Allergan share, with the rest payable in Valeant shares.

The higher offer appeared to disappoint investors, which sent shares of both companies down. Allergan, which rejected Valeant’s earlier approach, said it would consider the new offer, which adds contingent value rights worth as much as $25 per share, based on the success of Allergan’s experimental new blindness drug, Darpin.

Valeant’s efforts are supported by Pershing Square, which acquired a 9.7% stake in Allergan with Valeant’s help. The two are now pursuing a non-binding shareholder referendum in favor of the pact.

“Allergan shareholders want this deal to occur, but they want a higher price and the optionality on Darpin,” Valeant CEO Michael Pearson said. “We think the offer we made this morning address both of those concerns.”

Pershing Square chief William Ackman attended Valeant’s announcement but did not comment.

In Depth

Financial Industry Blockchain Consortium R3 To Open-Source Platform Code

Oct 20 2016 | 9:03pm ET

Bitcoin's blockchain technology has spawned a flurry of activity among fintech startups...


Hedge Funds Swarm Into Palm Beach

Oct 27 2016 | 2:32pm ET

As the first flakes of snow fall on New York's northern suburbs, Dan Weil of South...

Guest Contributor

Hedge Fund Marketing – Tips for Your Initial Sales Meeting

Sep 29 2016 | 5:46pm ET

There are two main goals a hedge fund should have for an initial in-person sales...